CDK1/2/4 inhibitor AG-024322
Term · Oncology and biomedicine · MLC-T-ONC-012439
A cyclin-dependent kinase (CDK) inhibitor with antineoplastic activity. AG-024322 selectively inhibits cyclin-dependent kinases (particularly CDK1,2 and 4), enzymes that regulate cell cycle progression. Inhibition of CDK may result in cell cycle arrest, induction of apoptosis, and inhibition of DNA replication and tumor cell proliferation.
| Identifier | MLC-T-ONC-012439 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012439",
"term": "CDK1/2/4 inhibitor AG-024322",
"field": "Oncology and biomedicine",
"definition": "A cyclin-dependent kinase (CDK) inhibitor with antineoplastic activity. AG-024322 selectively inhibits cyclin-dependent kinases (particularly CDK1,2 and 4), enzymes that regulate cell cycle progression. Inhibition of CDK may result in cell cycle arrest, induction of apoptosis, and inhibition of DNA replication and tumor cell proliferation.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/cdk1-2-4-inhibitor-ag-024322/"
}
Record 4,467 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.